Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

David U'Prichard

Dec 21, 2006
Premium
Drug developer CoGenesys said that David U’Prichard has been appointed to the company’s board of directors.
 
U’Prichard currently sits on the boards of Invitrogen and SR Pharma, the parent firm of Atugen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Earlier in the US

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

How the Proteins Shape Up

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

Who's to Be First?

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

PNAS Papers on Ovarian Cancer, Retrotransposon Insertions in Cancer, Malaria Mosquitoes

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.

Dec
03
Featured Webinar

Leveraging Multi-Omic Approaches to Understand Disease Stem Cells in Myeloid Malignancies

Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion. 

Dec
10
Featured Webinar

Accelerating Forward Engineering and Genome Discovery with CRISPR: E. Coli Case Studies

Sponsored by
Tecan

CRISPR has developed into a core tool to facilitate genome editing, inspiring transformative ideas in engineering biology. 

What's Popular?

In Gene Silencing/Gene Editing

  1. Horizon Discovery Licenses Gene-Edited Cell Line to Sanyou Biopharmaceuticals

  2. ERS Genomics Licenses CRISPR Patents to German Startup Vivlion

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.